BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
NESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ('BiomX' or the 'Company'), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will report fourth quarter and full year 2024 financial results and provide business and program updates on Tuesday, March 25, 2025.
A press release reporting the results will be available in the Investors section of the Company's website at www.biomx.com. The Company intends to host a conference call and a live audio webcast on a later date to report fourth quarter and full year 2024 financial results, in conjunction with its expected announcement of initial topline results from its Phase 2 trial for subjects with diabetic foot osteomyelitis.
About BiomXBiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT ('BacteriOphage Lead to Treatment') platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.
BiomX, Inc.Ben Cohenbenc@biomx.com
CORE IRMike Masonir-biomx@biomx.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Tech companies have a new hiring requirement: vibe coding
Looking for a tech job? Being good at vibe coding could help. Vibe coding is the art of using AI to generate code. It's the latest trend taking over Silicon Valley, and CTOs are taking notice. Business Insider found job listings from Visa, Reddit, DoorDash, and a host of others that explicitly require vibe coding experience or familiarity with AI code generators like Cursor and Bolt. One startup even called vibe coding a "non-negotiable" skill and required anyone hired to the position to generate at least half of their current code with AI. The listings make clear that companies want to hire these vibe coders to boost the speed at which they build their products, or what's known as "velocity" in the tech industry. Big Tech is getting in on the action too, with Google CEO Sundar Pichai saying he's had a "delightful" time vibe coding up a webpage and Amazon in talks to deploy Cursor. (Business Insider couldn't find any " Magnificent Seven" firms asking for vibe coding experience in their job ads, though.) While vibe coding gains traction, it's not close to replacing senior engineers just yet. Engineers tell BI that the practice remains mostly useful for spending less time on basic tasks. Vibe coding is now "essential" Visa posted three generative AI engineer positions last month for its Austin office that lists familiarity with vibe coding tools as "essential." Reddit, meanwhile, seeks an engineer who can build and maintain integrations with AI coding tools including Cursor and Bolt. Reddit wants this engineer to engage directly with the broader vibe-coding community to gather feedback and "drive adoption." DoorDash seeks an engineer familiar with those tools, too, while cybersecurity unicorn Snyk wants to hire someone with "deep expertise" in vibe coding. The most extreme embrace of vibe coding may come from Y Combinator startup Domu Technology, which called"vibe coding experience" a "non-negotiable." The listing said that at least half of this person's code should already be written by AI. It's all about speed There's a common thread across these listings: speed. Most mention that the company seeks people with vibe coding knowledge so its engineering teams can ship products out faster. That's why vibe coding is kicking off in the first place: to turbocharge engineering teams. For example, streaming service Tubi wants an engineer to integrate AI-powered coding tools into the daily workflow to "boost velocity." And Udacity wants to "accelerate" product development by hiring someone familiar with Cursor and Anthropic's AI assistant, Claude Code. The Visa positions that mention vibe coding also specify that it's for the "rapid" generation of code and prototypes at the company. Alex Balazs, CTO of Intuit, told BI he's approved six to seven different AI coding tools at Intuit including Cursor, Windsurf, and Microsoft Copilot — and he has no regrets. "Right now, we're seeing that a great engineer using one of these tools can be up to 40% faster in terms of coding," Balazs said. Balazs added that while Intuit doesn't specifically seek out vibe coders in its hiring, it does appreciate people who "love leveraging AI" to solve problems. AI isn't taking over just yet That's not to say someone with no coding experience armed with a $20-a-month Cursor subscription can waltz into a senior software engineer job. Vibe coding is relevant for companies largely because it helps existing engineers spend less time on "boilerplate code" and focus on higher-end problems instead, Balazs said. Even the most advanced vibe coding tools aren't so useful for tasks like shipping production-ready code or diving deep into a company's core systems, said Mohammad Sanatkar, a former senior machine learning engineer at Waymo who now runs an AI agents startup called SelfMachines in San Francisco. He said these tools tend to work better for simpler tasks, like building a website's front page. "A few weeks ago, I used Cursor for a landing page, and it was pretty good at it," he said. "But I don't think they are skilled enough to do core software improvements."
News24
an hour ago
- News24
Graphs that paint the picture of HIV in SA: Part 2
Eight million people living with HIV. Just over 6 million on treatment. Behind these big numbers lurk a universe of fascinating epidemiological dynamics. In this special briefing, Spotlight editor Marcus Low unpacks what we know about the state of HIV in South Africa. This is part 2 of 3. In Part 1 of this Spotlight special briefing, we looked at some of the big picture dynamics of HIV in South Africa. Most of the news there was good. In Part 2, however, we look at why making progress is getting harder and consider some key vulnerabilities of our HIV programme. The final 10% or 20% will be the hardest Spotlight The above graph shows the number of people starting treatment by year. As you can see, around a decade ago, this number was often higher than 500 000. Since 2021, it has been below 300 000. Government could no doubt do a better job at helping people start and stay on treatment, but there are also good epidemiological reasons for the slow-down. In short, those who were sicker or more eager to start treatment - and for whom taking treatment is relatively easy - are mostly already on treatment. Those who are not on treatment are likely less motivated to take treatment or may have challenges in their lives that make it hard for them to start and stay on treatment. Convincing and supporting this latter group to start and stay on treatment is quite simply harder than it is for the prior group, but it is where the focus will have to be if we are to get our numbers higher. It is one reason why many are so concerned about recent aid cuts that have disproportionately impacted HIV services for marginalised groups like sex workers, people who use drugs, and men who have sex with men. These groups of people often feel unwelcome at public sector clinics. One key thing to keep in mind when looking at HIV numbers is that people cycle in and out of HIV treatment a lot. A misleading impression can, for example, be created if one looks at the number of people starting or restarting treatment without subtracting the number of people who have stopped taking treatment over the same period. It is for this reason that it is best to focus mainly on the total number of people on treatment and how that number changes from year to year (you can see a graph of this in Part 1 of this series). Finally, another important nuance in the numbers is how much damage has been done to people's immune systems by the time they start treatment – the earlier you start, the better your long-term prognosis. It is concerning that, of the 241 000 people who started treatment in 2023/2024, 54 000 had CD4 counts below 200 cells per cubic millimetre, an indication that their immune systems had already been hit hard. Bigger programme, bigger vulnerabilities? Much of how an epidemic grows or wanes depends on how many people are infectious at a specific point in time. Generally, the more infectious people there are in a population, the more other people will get infected. It follows that, if you can't cure people, the next best thing from an epidemiological control perspective, is to make people non-infectious. (See our recent Special Briefing on the search for an HIV cure.) Fortunately, apart from keeping people healthy, consistently taking antiretroviral medicines also make the vast majority of people living with HIV non-infectious. Thus, while all eight million people living with HIV in South Africa could potentially become infectious, antiretroviral treatment means that only around two million of them actually are. Spotlight It is very unlikely that we will drop from 6.2 million people on treatment to 5.2, or even 5.5, but even just dropping by 100 000 or 200 000, will mean 100 000 or 200 000 more people become infectious. That would give our HIV epidemic a blast of oxygen it wouldn't have had otherwise. There are real vulnerabilities here. According to preliminary modelling that the Department of Health commissioned in response to US funding cuts, failure to replace the HIV services that were funded by the US in South Africa could result in an additional 150 000 to 295 000 additional infections by 2028. It will take a year or two before we see the actual impact of the aid cuts in data sources such as Thembisa, but, as reported by Daily Maverick, there have been some early indications from the country's public lab service that important numbers are down. *Check back tomorrow for Part 3 of this series. You can also find the complete version of this #InTheSpotlight special briefing as a single page on the Spotlight website. Note: All of the above graphs are based on outputs from version 4.8 of the Thembisa model published in March 2025. We thank the Thembisa team for sharing their outputs so freely. Graphs were produced by Spotlight using the R package ggplot2. You are free to reuse and republish the graphs. For ease of use, you can download them as a Microsoft PowerPoint slide deck. Technical note: The Thembisa model outputs include both stock and flow variables. This is why we have at some places written 2024 (for stock variables) and 2023/2024 (for flow variables). 2024 should be read as mid-2024. 2023/2024 should be read as the period from mid-2023 to mid-2024. Show Comments ()
Yahoo
an hour ago
- Yahoo
IgA Nephropathy Market Analysis Report 2025-2035: Innovation in Renal Therapies and Accelerated Drug Approvals Drive Growth
The global IgA nephropathy market is in growth due to rising awareness, better diagnostics, and advanced treatments like complement inhibitors. North America leads the market, supported by regulatory advantages. Key players such as Novartis are driving innovation, though high costs and competition remain challenges. Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "IgA Nephropathy Market - A Global and Regional Analysis: Focus on Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to global IgA nephropathy market is currently in the growth stage of its lifecycle, driven by increasing awareness, improved diagnostic capabilities, and advancements in renal treatment options. The market is expanding as novel therapies, such as complement inhibitors and non-immunosuppressive drugs, are gaining traction, addressing the unmet need for more effective renal treatments. With ongoing research and development, pharmaceutical companies are investing heavily in clinical trials to bring new, targeted therapies to market. The global IgA nephropathy market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare regulatory bodies are accelerating the approval process for innovative renal drugs, further fueling market growth. Despite this positive momentum, challenges such as high treatment costs and the variability in disease progression may hinder rapid expansion. As a result, the market is expected to continue growing, although competition and price pressures will likely intensify as more treatments emerge. North America is expected to dominate the global IgA nephropathy market during the forecast period due to its advanced healthcare infrastructure, high prevalence, and increased awareness of the disease. The region also benefits from regulatory advantages and a strong pharmaceutical presence, which accelerates the availability of effective treatments and drives the growth of the global IgA nephropathy market. How Can This Report Add Value to an Organization?Product/Innovation Strategy: Product launches and innovations in the global IgA nephropathy market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Novartis, and Travere Therapeutics, Inc., have been involved in the development of therapies for IgA Strategy: Enterprises led by market leaders in the global IgA nephropathy market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the Developments Regulatory Activities: In April 2025, the U.S. FDA granted accelerated approval for Novartis' Vanrafia (atrasentan) for the treatment of primary immunoglobulin A nephropathy. Partnerships: In March 2025, Folia Health and Novartis Pharmaceuticals, Inc. announced their collaboration on an innovative at-home observational real-world evidence initiative aimed at supporting individuals with IgA nephropathy. Regulatory Activities: In November 2024, South Korea approved Everest Medicines' NEFECON for the treatment of primary IgA nephropathy. Regulatory Activities: In September 2024, Ligand partner Travere Therapeutics received FDA approval for FILSPARI (sparsentan), the only non-immunosuppressive treatment that significantly slows kidney function decline in IgA nephropathy. Market Dynamics Drivers: Increasing Prevalence of IgA Nephropathy Continuous Advancements in Treatment Options Improved Diagnosis and Awareness Challenges: High Treatment Costs Limited Awareness in Developing Markets Key Market Players and Competition Synopsis Novartis F. Hoffmann-La Roche Ionis Pharmaceuticals Vertex Pharmaceuticals Otsuka Pharmaceutical Biogen Arrowhead Pharmaceuticals NovelMed Q32 Bio Walden Biosciences Takeda Pharmaceutical Vera Therapeutics Biocity Biopharmaceutics Co., Ltd. Calliditas Therapeutics AB Travere Therapeutics, Inc. Alexion Pharmaceuticals, Inc. Key Topics Covered: Executive SummaryScope and Definition1. Global IgA Nephropathy Market: Market Outlook1.1 Industry Outlook1.1.1 Market Overview and Ecosystem1.1.2 Market Trends1.1.3 Epidemiological Analysis of IgA Nephropathy1.1.3.1 By Region1.1.3.1.1 U.S.1.1.3.1.2 EU51.1.3.1.3 Rest-of-the-World1.1.4 Clinical Trials1.1.4.1 By Phase1.1.4.2 By Sponsor Type1.1.5 Regulatory Landscape / Compliance1.1.5.1 Legal Requirement and Framework in the U.S.1.1.5.2 Legal Requirement and Framework in the E.U.1.1.5.3 Legal Requirement and Framework in Asia-Pacific1.1.5.4 Legal Requirement and Framework in Rest-of-the-World1.2 Market Dynamics1.2.1 Impact Analysis1.2.2 Market Drivers1.2.3 Market Restraints1.2.4 Market Opportunities2. Global IgA Nephropathy Market (By Region), $Million, 2023-20352.1 North America2.1.1 Key Findings2.1.2 Market Dynamics2.1.3 Market Sizing and Forecast2.1.3.1 North America IgA Nephropathy Market (by Country)2.1.3.1.1 U.S.2.1.3.1.2 Canada2.2 Europe2.2.1 Key Findings2.2.2 Market Dynamics2.2.3 Market Sizing and Forecast2.2.3.1 Europe IgA Nephropathy Market (by Country)2.2.3.1.1 U.K.2.2.3.1.2 Germany2.2.3.1.3 France2.2.3.1.4 Italy2.2.3.1.5 Spain2.2.3.1.6 Rest-of-Europe2.3 Asia-Pacific2.3.1 Key Findings2.3.2 Market Dynamics2.3.3 Market Sizing and Forecast2.3.3.1 Asia-Pacific IgA Nephropathy Market (by Country)2.3.3.1.1 Japan2.3.3.1.2 China2.3.3.1.3 Rest-of-Asia-Pacific2.4 Rest-of-the-World2.4.1 Key Findings2.4.2 Market Dynamics2.4.3 Market Sizing and Forecast3. Global IgA Nephropathy Market - Competitive Benchmarking and Company Profiles3.1 Competitive Landscape3.1.1 Key Strategies and Developments by Company3.1.1.1 Funding Activities3.1.1.2 Mergers and Acquisitions3.1.1.3 Regulatory Approvals3.1.1.4 Partnerships, Collaborations and Business Expansions3.1.2 Key Developments Analysis3.2 Company Profiles3.2.1 Company Overview3.2.2 Product Portfolio3.2.3 Target Customers/End Users3.2.4 Analyst View4. Research MethodologyFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
